Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

New approaches to antibody therapy

Oncogene volume 19, pages 6144–6151 (2000)Cite this article

Abstract

Antibody-based therapy of human cancers has led to several remarkable outcomes, particularly in the therapy of breast cancer and lymphoma. Many solid tumors have proven less responsive, due in part to difficulties in the tumor-selective delivery of antibodies and potential cytolytic effectors. However, antibodies that directly perturb signaling mechanisms in cells derived from epithelial malignancies have shown benefit; examples include antibodies directed against the extracellular domains of HER2/neu and epidermal growth factor receptor. A long-term goal of immunotherapy has been to induce anti-tumor inflammatory responses that can directly cause tumor regression or induce adaptive responses against tumor-related antigens. This review focuses on the use of antibodies to provide a means for initiating anti-tumor immune responses, and on the use of antibodies as delivery vehicles of radionuclides.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Adams GP, McCartney JE, Tai M-S, Oppermann H, Huston JS, Stafford WF, Bookman MA, Fand I, Houston LL and Weiner LM. . 1993 Cancer Res. 53: 4026–4034.

  • Adams GP, McCartney JE, Wolf EJ, Eisenberg J, Huston JS, Stafford III WF, Bookman MA, Houston LL and Weiner LM. . 1995 Cancer Immunol. Immunother. 40: 299–306.

  • Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD and Weiner LM. . 1998a Cancer Res. 58: 485–490.

  • Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM and Marks JD. . 1998b Br. J. Cancer 77: 1405–1412.

  • Alpaugh RK, Schultz J, McAleer C, Giantonio BJ, Persson R, Burnite M, Nielsen SE, Vitek L, Persson B and Weiner LM. . 1998 Clin. Cancer Res. 4: 1903–1914.

  • Anderson W and Strand M. . 1987 Natl. Cancer Inst. Monogr. 3: 149–151.

  • Axworthy DB, Beaumier PL, Bottino BJ, Goshorn S, Mallett RW, Stone DM, Su F-M, Theodore LJ, Yau EK and Reno JM. . 1996 Tumor Targeting 2: 156–157.

  • Bagshawe KD. . 1993 Adv. Pharmacol. 24: 99–121.

  • Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Boden JA, Rogers GT, Burke PJ, Melton RG and Sherwood RF. . 1991 Disease Markers 9: 233–238.

  • Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC and Norton L. . 1996 J. Clin. Oncol. 14: 737–744.

  • Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJ and Robson L. . 1996 Nature Med. 2: 979–984.

  • Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, Eggermont AMM, Goey SH, Gratama JW, Lamers CHJ, Nooy MA, Parmiani G, Raspagliesi F, Ravagnani F, Scarfone G, Trimbos JP, Warnaar SO and Bolhuis RLH. . 1995 J. Natl. Cancer Inst. 87: 1463–1469.

  • Chalitta-Eid P, Abboud CA, Morrison SL, Penichet ML, Rosell KE, Poles T, Hilchey SP, Planelles V and Rosenblatt JD. . 1998 J. Immunol. 161: 3729–3736.

  • Clackson T, Hoogenboom HR, Griffiths AD and Winter G. . 1991 Nature 352: 624–628.

  • Clark JI, Alpaugh RK, von Mehren M, Schultz J, Gralow JR, Cheever MA, Ring DB and Weiner LM. . 1997 Cancer Immunol. Immunother. 44: 265–272.

  • Clynes R, Towers TL, Presta LG and Ravetch JV. . 2000 Nature Med. 6: 443–446.

  • Colcher D, Minelli FM, Roselli M, Muraro R, Simpson-Milenic D and Schlom J. . 1988 Cancer Res. 48: 4597–4603.

  • Curnow RT. . 1997 Cancer Immunol. Immunother. 4: 210–215.

  • Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR and Louie AC. . 1995 J. Clin. Oncol. 13: 688–696.

  • Gallinger S, Reilly RM, Kirsh JC, Odze RD, Hay K, Polihronis J, Damani MT, Shpitz B and Stern HS. . 1993 Cancer Res. 53: 271–278.

  • Garcia de Palazzo I, Gercel-Taylor C, Kitson J and Weiner LM. . 1990 Cancer Res. 50: 7123–7128.

  • Giantonio BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Guedez Y, Kotb M, Vitek L, Persson R, Kalland T, Dohlsten M, Persson B and Weiner LM. . 1997 J. Clin. Oncol. 15: 1994–2007.

  • Gillies SD, Reilly EB, Lo KM and Reisfeld RA. . 1992 Proc. Natl. Acad. Sci. USA 89: 1428–1432.

  • Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell Jr JR, Estes N, DeSimone P and Rayburn P. . 1978 New Engl. J. Med. 298: 1384–1386.

  • Goodwin DA, Meares CF, McCall MJ, McTigue M and Chaovapong W. . 1988 J. Nucl. Med. 29: 226–234.

  • Holliger P, Prospero T and Winter G. . 1993 Proc. Natl. Acad. Sci. USA 90: 6444–6448.

  • Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE and Wu AM. . 1996 Cancer Res. 56: 3055–3061.

  • Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E and Crea R. . 1988 Proc. Natl. Acad. Sci. USA 85: 5879–5883.

  • Jain RK. . 1987 Cancer Res. 47: 3039–3051.

  • Juweid M, Neumann R, Paik C, Perez-Bacete M, Sato J, van Osdol W and Weinstein JN. . 1992 Cancer Res. 52: 5144–5153.

  • Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, Glenn SD and Wahl RL. . 1993 New Engl. J. Med. 329: 459–465.

  • Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID and Weiner LM. . 2000 Clin. Cancer Res. 6: 406–414.

  • Kudo T, Saeki H and Tachibana T. . 1991 J. Immunolog. Methods 145: 119–125.

  • Lanzavecchia A and Scheidegger D. . 1987 Eur. J. Immunol. 17: 105–111.

  • Link BK, Kostelny SA, Cole MS, Fusselman WP, Tso JY and Weiner GJ. . 1998 Interntl J. Cancer 77: 251–256.

  • Link BK and Weiner GJ. . 1993 Blood 81: 3343–3349.

  • LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J and Khazaeli MB. . 1989 Proc. Natl. Acad. Sci. USA 86: 4220–4224.

  • Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A and Levy R. . 1994 Blood 84: 2457–2466.

  • Mack M, Riethmuller G and Kufer P. . 1995 Proc. Natl. Acad. Sci. USA 92: 7021–7025.

  • Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK and Springer CJ. . 1997 Cancer Chemother. Pharmacol. 40: 189–201.

  • Nitta T, Sato K, Yagita H, Okumura K and Ishii S. . 1990 Lancet 335: 368–371.

  • Obrist R, Schmidli J and Obrecht JP. . 1988 Biochem. Biophys. Res. Commun. 155: 1139–1144.

  • Order SE, Klein JL, Leichner PK, Frincke J, Lollo C and Carlo DJ. . 1986 Int. J. Radiat. Oncol., Biol., Phys. 12: 277–281.

  • Paganelli G, Riva P, Deleide G, Clivio A, Chiolerio F, Scassellati GA, Malcovati M and Siccardi AG. . 1988 Interntl J. Cancer 2: (suppl) 121–125.

  • Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fischer LD and Bernstein ID. . 1993 New Engl. J. Med. 329: 1219–1224.

  • Pressman D and Korngold L. . 1953 Cancer 6: 619–623.

  • Renner C, Jung W, Sahin U, van Lier R and Pfreundschuh M. . 1995 Eur. J. Immunol. 25: 2027–2033.

  • Sabzevari H, Gillies SD, Mueller BM, Pancook JD and Reisfeld RA. . 1994 Proc. Natl. Acad. Sci. USA 91: 9626–9639.

  • Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS, Larson SM, Oettgen HF and Old LJ. . 1991 J. Clin. Oncol. 9: 478–490.

  • Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM and Adams GP. . 1995 Immunotechnology 1: 73–81.

  • Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM and Marks JD. . 1996 J. Mol. Biol. 263: 551–567.

  • Sconocchia G, Titus JA and Segal DM. . 1994 J. Immunol. 153: 5473–5481.

  • Segal DM and Wunderlich JR. . 1988 Cancer Invest. 6: 83–92.

  • Shen L, Guyre PM, Anderson CL and Fanger MW. . 1986 J. Immunol. 137: 3378–3382.

  • Siemers NO, Kerr DE, Yarnold S, Stebbins MR, Vrudhula VM, Hellstrom I, Hellstrom KE and Senter PD. . 1997 Bioconjugate Chem. 8: 510–519.

  • Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K and Berger MS. . 1999 Blood 93: 3678–3684.

  • Silverstein AM. . 1994 Cell. Immunol. 174: 1–6.

  • Slamon DJ, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eirmann W, Wolter J, Baselga J and Norton L. . 1998 Proc. ASCO 17: A377.

  • Steplewski Z, Lubeck MD and Koprowski H. . 1983 Science 221: 865–867.

  • Thomas MC, Greten TF, Pardoll DM and Jaffee EM. . 1998 Hum. Gene Thera. 9: 835–843.

  • Tibben JG, Boerman OC, Claessens RAMJ, Corstens FHM, van Deuren M, de Mulder PHM, van der Meer JWM, Keijser KGG and Massuger LFAG. . 1993 J. Natl. Cancer Inst. 85: 1003–1004.

  • Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ and Houghton AN. . 1988 J. Clin. Oncol. 6: 1636–1648.

  • Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG and Fcalpha RI. . 1997 Blood 90: 4485–4492.

  • Valone FH, Kaufman PA, Guyre PA, Lewis LA, Memoli V, Deo Y, Graziano R, Fisher J, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Morley TL, Arvizu C and Fanger MW. . 1995 J. Clin. Oncol. 13: 2281–2292.

  • Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL and Tso JY. . 1994 J. Immunol. 152: 2385–2392.

  • Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P and De Palazzo IG. . 1993a Cancer Res. 53: 94–100.

  • Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB and Alpaugh RK. . 1993b J. Immunol. 151: 1–9.

  • Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB and Alpaugh RK. . 1995a Cancer Res. 55: 4586–4593.

  • Weiner LM, Houston LL, Huston JS, McCartney JE, Tai M-S, Apell G, Stafford WF, Bookman MA, Gallo JM and Adams GP. . 1995b Tumor Targeting 1: 51–60.

  • Weiner LM, Steplewski Z, Koprowski H, Sears HF, Litwin S and Comis RL. . 1986 Hybridoma 5: (Suppl. 1) 65–77.

  • Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E and Grillo-Lopez AJ. . 1999 J. Clin. Oncol. 17: 3793–3803.

  • Wu AM, Chen W, Raubitschek AA, Willams LE, Fischer R, Hu S-Z, Odom-Maryon T, Wong JYC and Shively JE. . 1996 Immunotechnology 2: 21–36.

Download references

Acknowledgements

Supported by NIH grants CA06927, CA50633, CA65559, by the Department of Defense, by an appropriation from the Commonwealth of Pennsylvania, by the Frank Strick Foundation and by the Bernard A and Rebecca S Bernard Foundation.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, Pennsylvania, USA

    Louis M Weiner & Gregory P Adams

Authors
  1. Louis M Weiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory P Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weiner, L., Adams, G. New approaches to antibody therapy. Oncogene 19, 6144–6151 (2000). https://doi.org/10.1038/sj.onc.1204000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204000

Keywords

This article is cited by

Search

Advanced search

Quick links